

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)



(10) International Publication Number
WO 2021/214277 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2021/060637

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
23 April 2021 (23.04.2021)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20171356.7 24 April 2020 (24.04.2020) EP

(71) Applicant (for all designated States except US): **F. HOFF-
MANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse
124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE
INC.** [US/US]; Overlook at Great Notch, 150 Clove Road,
Little Falls, New Jersey 07424 (US).

(72) Inventor: **SHAO, Zhixin**; c/o Roche Diagnostics GmbH,
Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **VOSSIUS & PARTNER PATENTANWÄLTE
RECHTSANWÄLTE MBB**; Siebertstrasse 3, 81675
München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ENZYME AND PATHWAY MODULATION WITH SULFHYDRYL COMPOUNDS AND THEIR DERIVATIVES

(57) Abstract: The present invention relates to proteins, particularly antibodies such as anti-CD20/anti-CD3 bispecific antibodies and anti α -synuclein antibodies, having monogalactosylated (G1) and digalactosylated (G2) glycans. More particular, the present invention relates to galactosylation engineering to generate proteins with improved therapeutic properties, including proteins with increased titer. Further, the invention relates to a cell culture medium and a mammalian cell as well as methods using said cell culture medium and said mammalian cell for producing said proteins. Moreover, the present invention relates to the use of said antibodies as a medicament such as for the treatment of cancer, particularly cancer associated with B-cells, or Parkinson's disease.



WO 2021/214277 A1